It would also be important to determine whether patient outcome is dependent on a treatment plan that is specific to JIA category or extra-articular manifestations versus level of active joints or disease pattern, for example, the prescription of IL-1β and IL-6 inhibitors in systemic JIA, which could serve to influence clinical decision making in the future. This evidence concerns the gene IL6 and juvenile idiopathic arthritis.